Search results for: Ofloxacin CAS Number [82419 36 1]
#27241648 
//
To Up
A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India.
Pre-extensively drug resistant (pre-XDR) and extensively drug resistant tuberculosis (XDR-TB) have been areas of growing concern, and are posing threat to global efforts of TB control. The present study was planned to study the presence of pre-XDR and XDR Mycobacterium tuberculosis and their genotypes in clinical isolates obtained from previously treated cases of pulmonary TB.Parul Singhal, Pratima Dixit, Pooja Singh, Indu Jaiswal, Mastan Singh, Amita Jain
2114 related Products with: A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India.
Related Pathways
#8369012 //
To Up
Influence of ofloxacin on chloroplasts and mitochondria in Euglena gracilis.
Ofloxacin (CAS 83380-47-6), a representative of new quinolones, which exerts inhibitory activity against DNA gyrase in bacteria, damages both semiautonomous organelles in Euglena gracilis: chloroplasts and partly mitochondria. The action of ofloxacin on these organelles was analysed by transmission electron microscopy. The first symptoms of ofloxacin treatment were mass aberrations of chloroplasts with subsequent diluting out of these pathological organelles from the cells, so giving rise to the heterotrophic mutants. The loss of chloroplasts is hereditary. Changes in ultrastructure of mitochondria were observed too. Cup-like (in sections ring-like) mitochondria represented the most frequent abnormalities of these organelles induced by the drug. After repeated subcultivations on ofloxacin-free media the number of damaged mitochondria gradually decreased to the normal.L Ebringer, J Polónyi, J Krajcovic
1890 related Products with: Influence of ofloxacin on chloroplasts and mitochondria in Euglena gracilis.
10 ug 5 G100ug1 mg5mg100 μg1 ml5100 μg100ug100 μg
Related Pathways
#1622438 //
To Up
Effect of the new quinolone antibacterial agent levofloxacin on multiple organ carcinogenesis initiated with wide-spectrum carcinogens in rats.
A multiple organ carcinogenesis model was used in male F344 rats to test the carcinogenic potential of (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- 7H-pyrido[1,2,3-de][1,4] benzoxazine-6-carboxylic acid hemihydrate (levofloxacin, DR-3355, CAS 10086-85-4). After sequential treatment with diethylnitrosamine (DEN: carcinogen for the liver), N-methylnitrosourea (MNU: carcinogen for the esophagus, forestomach and thyroid) and dihydroxy-di-N-propylnitrosamine (DHPN: carcinogen for the lungs, kidney and urinary bladder), rats were treated with DR-3355, N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), catechol (CC) or phenobarbital (PB) to examine whether these compounds modified the carcinogenesis in multiple organs. As a result of histopathological examinations at study week 20, DR-3355 did not induce neoplastic lesions, nor did it enhance the occurrences of proliferative preneoplastic lesions. In contrast, BBN increased the incidences of hyperplasias and papillomas of the urinary bladder. CC enhanced the occurrences of hyperplasias and papillomas of the forestomach as well as submucosal glandular growth for the glandular stomach. PB increased the number of altered cell foci in the liver and the incidence of follicular cysts and hyperplasias of the thyroid. These results indicate that DR-3355 is not capable of promoting the development of tumors in rat multiple organs.T Kajimura, H Tojo, G Kudo, M Yamada, S Domon, M Nomura, S Takayama
1603 related Products with: Effect of the new quinolone antibacterial agent levofloxacin on multiple organ carcinogenesis initiated with wide-spectrum carcinogens in rats.
Related Pathways
#1622434 //
To Up
Twenty-six-week oral toxicity of the new quinolone antibacterial agent levofloxacin in rats and cynomolgus monkeys.
The oral 26-week toxicity of (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4- methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid hemihydrate (levofloxacin, DR-3355, CAS 100986-85-4) was investigated in rats and monkeys. Rats receiving higher doses of DR-3355 exhibited an increased number of larger fecal pellets, salivation, lower neutrophil counts, enlargement of the cecum and prominent goblet cells in the cecal mucosa. Monkeys did not show any changes due to DR-3355 treatment. Therefore, a no-effect dose of DR-3355 under these conditions was determined as 20 mg/kg in the rat and 62.5 mg/kg in the cynomolgus monkey.M Kato, K Furuhama, A P Woolley, R Ashby, J S Fowler, S Takayama